Summary of study ST000927

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000642. The data can be accessed directly via it's Project DOI: 10.21228/M8PM4T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Show all samples  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data
Study IDST000927
Study TitleProbing the metabolic phenotype of breast cancer cells by multiple tracer stable isotope resolved metabolomics (part II)
Study SummaryBreast cancers vary by their origin and specific set of genetic lesions, which gives rise to distinct phenotypes and differential response to targeted and untargeted chemotherapies. To explore the functional differences of different breast cell types, we performed Stable Isotope Resolved Metabolomics (SIRM) studies of one primary breast (HMEC) and three breast cancer cells (MCF-7, MDAMB-231, and ZR75-1) having distinct genotypes and growth characteristics, using 13C6-glucose, 13C-1+2-glucose, 13C5,15N2-Gln, 13C3-glycerol, and 13C8-octanoate as tracers. These tracers were designed to probe the central energy producing and anabolic pathways (glycolysis, pentose phosphate pathway, Krebs Cycle, glutaminolysis, nucleotide synthesis and lipid turnover). We found that glycolysis was not associated with the rate of breast cancer cell proliferation, glutaminolysis did not support lipid synthesis in primary breast or breast cancer cells, but was a major contributor to pyrimidine ring synthesis in all cell types; anaplerotic pyruvate carboxylation was activated in breast cancer versus primary cells. We also found that glucose metabolism in individual breast cancer cell lines differed between in vitro cultures and tumor xenografts, but not the metabolic distinctions between cell lines, which may reflect the influence of tumor architecture/microenvironment.
Institute
University of Kentucky
Last NameLane
First NameAndrew
AddressRm 516 Biopharm Complex, 789 S. Limestone St.,Univ. of Kentucky, Lexington, KY 40536
Emailandrewlane@gmail.com
Phone8592182868
Submit Date2018-01-24
Analysis Type DetailNMR
Release Date2018-06-05
Release Version1
Andrew Lane Andrew Lane
https://dx.doi.org/10.21228/M8PM4T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000642
Project DOI:doi: 10.21228/M8PM4T
Project Title:Breast Cancer Metabolism
Project Summary:The program comprises three project areas utilizing stable isotope resolved metabolomics to gain a mechanistic understanding of NSCLC in situ. The projects combine cell culture, animal models and human subjects to define the influence of the tumor microenvironment on cancer progression.
Institute:University of Kentucky
Last Name:Lane
First Name:Andrew
Address:Rm 516 Biopharm Complex, 789 S. Limestone St.,Univ. of Kentucky, Lexington, KY 40536
Email:andrewlane@gmail.com
Phone:8592182868
  logo